NCT07192016View on ClinicalTrials.gov

129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2026

Primary Completion Date

September 30, 2027

Study Completion Date

October 31, 2027

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg

The investigational drug is a single Ellipta inhaler containing 100 ug fluticasone furoate(inhaled corticosteroid), 62.5 ug umeclidinium(long-acting muscarinic antagonist) and 25 ug vilanterol(long-acting β2-adrenergic agonist). The drug is delivered in an Ellipta inhaler in a single dose once daily.

All Listed Sponsors
lead

Western University, Canada

OTHER